BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Dowpharma 

The Dow Chemical Company
5501 Oberlin Drive
San Diego  California  92121  U.S.A.
Phone: 800-745-7475 Fax: 858-352-4560


SEARCH JOBS

View Clinical Trials from BioPharm Insight

DowpharmaSM contract manufacturing services delivers innovative technologies, products, and services in drug discovery, development, delivery and manufacturing to pharmaceutical and biopharmaceutical companies. Dowpharma has one of the broadest and deepest capabilities in the global outsourcing industry with services that include process development, route selection, methods development, custom solubilization, chiral capabilities, and associated analytical services, as well as manufacturing and scale-up from feasibility, through clinical trials, to commercial manufacturing. Customers can leverage Dowpharma's experience and track record to transport their biopharmaceuticals from discovery to commercialization.

Dowpharma offers a broad spectrum of process development and manufacturing services for the production of recombinant proteins, peptides and vaccines from microbial hosts.

    o Dowpharma uses a systems biology approach to Process Development
    o Application of Bioinformatics, Genomics, Functional Genomics, and Genome Scale Metabolic Modeling
    o Unmatched fermentation infrastructure enabling innovative experimental design and rapid execution
    o World class analytical capability enables complete characterization of proteins
    o Structured and disciplined project execution teams


Dowpharma's Pfenex Expression Technology™, a Pseudomonas-based technology for the production of recombinant proteins is built around specially designed strains of Pseudomonas fluorescens.

Pfenex Expression Technology ...

    ... improves yields through very high cell density fermentation and higher specific protein expression per cell.
    ... avoids the complexity and inefficiency of protein refolding through soluble expression
    ... enables expression of hard-to-express proteins, peptides, Fab's, single chain fragments and antigens.
    ... full set of applicable host vectors and promoters
    ... does not require the use of antibiotics or animal derived components at any point in the production process.


Pfenex Expression Technology is a cost-effective alternative to traditional synthetic methods and a more efficient option for the long term for the production of peptides with greater than 25 amino acids. The improved yields translate into lower cost of goods, while strain optimization helps to eliminate production problems early and avoid costly delays on the back end. This technology can be combined with other Dowpharma technologies, such as PEGylation, to positively impact a product's bottom line.

Dowpharma also develops high quality activated PEGs with fully characterized functionality and lot-to-lot consistency. PEGs are a proven drug delivery technology that can extend the half-life of a drug candidate and reduce dosing frequency. Customers can take advantage of Dowpharma's royalty-free pricing and complete PEGylation conjugation services and support to PEGylate a protein, peptide, antibody or oligonucleotide fragment-based biopharmaceutical. Molecular weights can range from 5 to 40 kDa.

The biopharmaceutical activities for Dowpharma are headquartered in San Diego. Dowpharma is focused on becoming a process development partner with its customers, providing control and flexibility in enhancing the expression and production of therapeutics. Dowpharma has the infrastructure to handle the rapid and linear scale-up of process development programs. This includes industry-experienced scientists to assist customers every step of the way - analytical development, process development, process scale-up, and ultimately technology transfer to a cGMP manufacturing facility, such as those in Dow's external Contract Manufacturing Network. Customers can choose when and where to access Dowpharma's expertise along this process development pathway.

Dowpharma's San Diego site consists of four facilities housing commercial, project management and operational staff, as well as researchers and scientists working and operating in microbiology laboratories and small- and medium-scale pilot plants. Capabilities at the site include:

    o Molecular Biology
    o Bioprocessing, including process development and scale-up for fermentation (20L- 1500L), recovery and purification for microbial based processes
    o Analytical Method Development
    o Pfenex Expression Technology for the production of therapeutic proteins, peptides, scFv's and fAb's.
    o Solvent Extraction Technology for the efficient recovery of protein from production media.


Last Updated: 09-08-05


 Key Statistics


Email: dowpharma@dow.com
Ownership: Subsidiary

Web Site: Dowpharma
Employees: 43,000
Symbol: DOW
 









 Company News
Viventia Biotech Inc. (VBI.TO) And Dowpharma (DOW)(SM) Announce A Multi-Product Commercial License Agreement Using Pfenex Expression Technology(TM) From Dowpharma (DOW) 2/14/2006 2:31:16 PM
Alnylam Pharmaceuticals (ALNY) Announces Manufacturing Agreement With Dowpharma (DOW) For RNAi Therapeutics10/19/2005 5:13:09 PM
Dowpharma (DOW) Announces Agreement With Pfizer Inc. (PFE) Using Pfenex Expression Technology(TM) And Dow Solvent Extraction Technology10/19/2005 5:12:56 PM
Dowpharma (DOW) Selects Mentus As Agency Of Record10/19/2005 5:12:29 PM
Dowpharma (DOW) Consolidates Biopharmaceutical Process Development To San Diego10/19/2005 5:11:29 PM
Dowpharma (DOW) Closes Smithfield Plant; Cuts Jobs10/19/2005 5:11:20 PM
Andrew N. Liveris Elected Dow Chemical Company (DOW) President And COO; William S. Stavropoulos Continues As Chairman And CEO10/19/2005 5:10:28 PM
Dowpharma (DOW) And Cytogen Corporation (CYTO) Agree To Develop PSMA Antibody For Treatment Of Cancer10/19/2005 5:10:22 PM
Dow Chemical Company (San Diego, California) (DOW) To Produce Nobex Corporation Peptide In Plant-Based System10/19/2005 5:10:01 PM
Dowpharma (DOW) Introduces Next Generation Microbial Expression System For Production Of Biotherapeutics10/19/2005 5:09:43 PM
12